Literature DB >> 10506554

Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade.

P Hertel1, M V Fagerquist, T H Svensson.   

Abstract

Clozapine exerts superior clinical efficacy and markedly enhances cortical dopamine output compared with classical antipsychotic drugs. Here the alpha2 adrenoceptor antagonist idazoxan was administered to rats alone or in combination with the D2/3 dopamine receptor antagonist raclopride. Dopamine efflux in the medial prefrontal cortex and conditioned avoidance responding were analyzed. Idazoxan selectively potentiated the cortical output of dopamine and augmented the suppression of conditioned avoidance responding induced by raclopride. These results challenge basic assumptions underlying the dopamine hypothesis of schizophrenia and provide insight into clozapine's mode of action.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10506554     DOI: 10.1126/science.286.5437.105

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  37 in total

1.  The neurotensin-1 receptor agonist PD149163 inhibits conditioned avoidance responding without producing catalepsy in rats.

Authors:  Elizabeth N Holly; Bree Ebrecht; Adam J Prus
Journal:  Eur Neuropsychopharmacol       Date:  2011-01-28       Impact factor: 4.600

2.  Influence of phasic and tonic dopamine release on receptor activation.

Authors:  Jakob K Dreyer; Kjartan F Herrik; Rune W Berg; Jørn D Hounsgaard
Journal:  J Neurosci       Date:  2010-10-20       Impact factor: 6.167

3.  Effect of clozapine on interval timing and working memory for time in the peak-interval procedure with gaps.

Authors:  Catalin V Buhusi; Warren H Meck
Journal:  Behav Processes       Date:  2006-10-14       Impact factor: 1.777

4.  Adrenergic modulation of NMDA receptors in prefrontal cortex is differentially regulated by RGS proteins and spinophilin.

Authors:  Wenhua Liu; Eunice Y Yuen; Patrick B Allen; Jian Feng; Paul Greengard; Zhen Yan
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-13       Impact factor: 11.205

5.  Serotonergic influence on the potentiation of D-amphetamine and apomorphine-induced rotational behavior by the alpha2-adrenoceptor antagonist 2-methoxy idazoxan in hemiparkinsonian rats.

Authors:  J Srinivasan; W J Schmidt
Journal:  J Neural Transm (Vienna)       Date:  2004-12-22       Impact factor: 3.575

Review 6.  Dopamine receptors: important antihypertensive counterbalance against hypertensive factors.

Authors:  Chunyu Zeng; Pedro A Jose
Journal:  Hypertension       Date:  2010-11-22       Impact factor: 10.190

Review 7.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

8.  Yohimbine disrupts prepulse inhibition in rats via action at 5-HT1A receptors, not alpha2-adrenoceptors.

Authors:  Susan B Powell; Javier Palomo; Barbara S Carasso; Vaishali P Bakshi; Mark A Geyer
Journal:  Psychopharmacology (Berl)       Date:  2005-02-18       Impact factor: 4.530

9.  Anticataleptic properties of alpha2 adrenergic antagonists in the crossed leg position and bar tests: differential mediation by 5-HT1A receptor activation.

Authors:  Mark S Kleven; Marie-Bernadette Assié; Cristina Cosi; Catherine Barret-Grévoz; Adrian Newman-Tancredi
Journal:  Psychopharmacology (Berl)       Date:  2004-09-24       Impact factor: 4.530

10.  The effect of the alpha2-adrenoreceptor antagonist idazoxan against 6-hydroxydopamine-induced Parkinsonism in rats: multiple facets of action?

Authors:  J Srinivasan; Werner J Schmidt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-04-29       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.